Consistent in their evaluation, an analyst from UBS keeps a Buy rating on Moderna with a target price of $78. * In a cautious move, an analyst from Goldman Sachs downgraded its rating to Neutral ...

Nutanix jumped 14% after posting fiscal second-quarter earnings and revenue that beat analysts' forecasts. Nvidia reported sharply higher quarterly sales and profit, but a narrower profit margin.

Improving economic conditions and a more favorable regulatory environment give Goldman Sachs catalysts to benefit from in the ...

Goldman Sachs is building a new campus to house its rapidly expanding Dallas office. Two top executives walked BI through the ...

Expectations of a banner year in dealmaking have not yet materialized due to worries about inflation and uncertainties over U ...

Goldman Sachs analysts added ResMed (RMD) to the firm’s APAC Conviction List as part of its monthly update. The firm expects “robust” ...

Discover why Goldman Sachs remains a top pick with strong ratings, impressive margins, and growth potential in M&A, equity ...

Goldman Sachs Group Inc. said it’s more than 80% of the way to meeting its 2030 goal of putting $750 billion toward ...

Goldman Sachs Asset Management is launching its first biodiversity fund for bond investors, in a move it says provides a new product to a market that’s so far been dominated by other asset classes.

Goldman Sachs analyst Chris Shibutani initiated coverage of Metsera (MTSR) as an Early-Stage Biotech. Metsera is clinical-stage ...

Our research team assigns Bronze ratings to strategies they’re confident will outperform a relevant index, or most peers, over a market cycle on a risk-adjusted basis. The comanagers on this ...